QUINAGLUTE
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Dec 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QUINAGLUTE is an oral extended-release tablet approved in 1969 by Bayer. The generic name and mechanism of action are not publicly documented in available records. Patient population and therapeutic indication cannot be determined from available data.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); commercial team likely in maintenance mode with potential for downsizing.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings and LOE-approaching lifecycle indicate this is a legacy asset with limited career growth or hiring momentum at Bayer. Professionals on QUINAGLUTE teams should anticipate portfolio rationalization and evaluate lateral moves to growth-stage franchises.
Brand ManagerField Sales Representative
Worked on QUINAGLUTE at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.